Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 147-163 , October 2010

Tumor Necrosis Factor Inhibitors and Lung Disease: A Paradox of Efficacy and Risk

  • Atul A. Khasnis, MD

      Affiliations

    • Fellow, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
    • ,
  • Leonard H. Calabrese, DO

      Affiliations

    • Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, RJ Fasenmyer Chair of Clinical Immunology Vice Chairman; Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
    • Corresponding Author InformationAddress reprint requests to: Leonard H. Calabrese, DO, 9500 Euclid Avenue, A 50, Cleveland, OH 44120

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The authors have no conflicts of interest to disclose.

PII: S0049-0172(09)00115-2

doi: 10.1016/j.semarthrit.2009.09.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 147-163 , October 2010

Article Tools

* Image Usage & Resolution